Prenatal exposure to antibiotics and risk of neurodevelopmental disorders in offspring: A systematic review and meta-analysis

Qiuji Tao¹,²†, Yajun Shen³,⁴,⁵†, Yang Li³, Huan Luo³, Meng Yuan³ and Jing Gan³,⁴,⁵*¹

¹Department of Pediatrics of Neurology Nursing, West China School of Nursing, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China, ²Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China, ³Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China, ⁴Key Laboratory of Obstetric and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, Sichuan, China, ⁵Key Laboratory of Development and Maternal and Child Diseases of Sichuan Province, Chengdu, Sichuan, China

Background and purpose: A growing body of research suggests that inflammation and maternal infections may lead to an increased risk of neurodevelopmental problems such as attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), cerebral palsy (CP), and epilepsy in offspring. The aim of this study was to observe the connection between prenatal antibiotic exposure and the risk of these neurodevelopmental disorders in offspring.

Patients and methods: A comprehensive search was conducted in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Google Scholar, and Scopus databases for observational studies that looked into the link between prenatal exposure to antibiotics and the risk of neurodevelopmental problems in offspring, published from 1 January 1950 to 31 January 2022. The Newcastle–Ottawa Scale (NOS) was used to assess the quality of the included studies. Data were analyzed using the STATA version 12 software, and an odds ratio (OR) with a 95% confidence interval (CI) was reported.

Results: A total of 15 studies were included in the meta-analysis. Prenatal antibiotic exposure was associated with the increased risk of ADHD (OR = 1.14; 95% CI = 1.13 to 1.15; \( \hat{I}^2 = 0% \)) and epilepsy (OR = 1.34; 95% CI = 1.02 to 1.66; \( \hat{I}^2 = 96.8% \)). The link between prenatal antibiotic exposure and the risk of ASD (OR = 1.09; 95% CI = 0.88 to 1.31; \( \hat{I}^2 = 78.9% \)) and CP (OR = 0.99; 95% CI = 0.56 to 1.43; \( \hat{I}^2 = 91% \)) was found to be non-significant. In all of the included prospective cohort studies, subgroup analysis suggested a significant association between prenatal
Introduction

A higher risk of neurological disorders has been related to severe viral and bacterial infections, as well as infections caused by parasites, particularly in hospitalized patients (1–3). Continuous complex neurodevelopmental processes such as axonal and dendritic growth, neurogenesis, synaptogenesis, and refinement of these synaptic connections make the prenatal period and infancy particularly vulnerable to exposure (4). Antibiotics, which account for 80% of all drugs provided to pregnant women, are commonly used to treat infections during pregnancy (5). It is projected that 19–49% of pregnant women are given antimicrobials during their pregnancy and that this number will continue to rise. Antibiotic usage during pregnancy has been linked to immune system changes, childhood asthma, changes in gut microbiota, obesity, and functional deficits in the offspring (6–11).

Numerous studies demonstrated that maternal infections and inflammation influence the development of the fetal brain, raising the chance of mental disorders, with a focus on neurodevelopmental diseases (1, 12–14). While some studies have found that the use of antimicrobials during pregnancy is associated with the increased risk of neurodevelopmental disorders including cerebral palsy (CP), attention-deficit/hyperactivity deficit (ADHD), autism spectrum disorder (ASD), and epilepsy, other studies did not find such association (11, 15–20).

Antibiotic exposure during pregnancy has been linked to the likelihood of ASD (21) and ADHD (22) in two recent meta-analyses. These reviews, however, reported data from a small number of studies and could not cover all key neurodevelopmental disorders, such as cerebral palsy and epilepsy. The goal of this systematic review and meta-analysis is to look at the association between prenatal antibiotic exposure and the risk of these neurodevelopmental disorders in offspring.

Materials and methods

Study design

This study involves a systematic review and meta-analysis for critical assessment and evaluation of all published reports that evaluate the association of prenatal antibiotic exposure with the risk of neurodevelopmental problems in offspring.

Ethical clearance

No ethical approval is needed for this systematic review and meta-analysis, as it was based on already published data.

Protocol and registration

We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (23) to conduct the study, with a PROSPERO number (CRD42022306248).

Eligibility criteria

Inclusion criteria

(a) Observational studies investigating the effect of prenatal antibiotic exposure and the risk of neurodevelopmental disorders in offspring. (b) Children diagnosed with any one of the neurodevelopmental disorders including ASD, ADHD, CP, and epilepsy based on prenatal antibiotic exposure. (c) The Control group defined as Offspring with no diagnosis of any neurodevelopmental or other psychiatric or genetic disorders.
Exclusion criteria
(a) Duplicate studies, systematic reviews, editorials, case series, case reports, conference abstracts, and preprints. (b) Studies that do not describe required outcomes. (c) Unavailability of full texts. (d) Animal studies. (e) Gray literature (reports, conference proceedings, and theses) and ongoing studies.

Search strategy
This systematic review was performed following the guidelines of the PRISMA (23) and Cochrane (24). An electronic search in Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Google Scholar, and Scopus databases was performed for articles published from 1 January 1950 to 31 January 2022, with no language restrictions. The following key terms were used: “antibiotic” OR “antimedicine” OR “antibacterial” AND “Neurodevelopmental disorders” OR “ADHD” OR “Attention-deficit hyperactivity” OR “hyperactivity” OR “inattention” AND “Cerebral Palsy” AND “Autism” AND “Seizure disorders” OR Epilepsy. Reference lists of the retrieved papers, prior meta-analyses, and review articles were manually searched for additional relevant studies.

Data extraction
Data were collected independently by two reviewers and included author name, country, study period, publication year, study design, diagnostic criteria, exposure assessment, sample size, age at the time of antibiotic exposure, outcomes, and crude or adjusted estimates for disease occurrence.

Risk of bias assessment
Two authors independently assessed the risk of bias using the Newcastle Ottawa Scale (NOS) (25). This scale is used to assess the quality of non-randomized studies for systematic review and meta-analysis and has three important components: group comparability, study group selection, and determination of the target outcome or exposure. Each study may receive a maximum of eight stars (high quality) to a minimum of 0 stars (poor quality). Any disagreements among the authors on the quality scores were resolved by discussion.

Statistical analysis
Statistical analysis was done using the STATA version 12 software. For pooled estimates, the odds ratio (OR) with a 95% confidence interval (CI) was generated. The I² statistic was used to calculate heterogeneity (26). This test determines how much of the difference in the study results is due to heterogeneity rather than sampling error. I² of <50% is seen as inconsequential, and I² of over 50% indicates moderate to significant heterogeneity. Publication bias was detected by funnel plot. By eliminating one study at a time, we performed sensitivity analyses to see how a single study affected the total risk estimates. P < 0.05 indicated statistical significance.

Results

Literature selection
As seen in Figure 1, the initial search yielded 287 results. Of them, 27 records were reviewed after duplicate removal, and 19 articles remained after the title and abstract screening. Finally, after evaluating full texts, four articles were removed due to insufficient data or overlapping data, and the remaining 15 studies were selected for the present meta-analysis.

Study characteristics
Fifteen observational studies (11, 15–20, 27–34) including six studies of ASD (11, 16, 19, 20, 29), four studies of ADHD (16, 17, 27, 28), four studies of CP (15, 16, 33, 34), and five studies of epilepsy (16, 30–32) were included in our systematic review. Three studies were retrospective cohort (15, 17, 30), three studies were case-control (11, 19, 34), one study was nested case-control (20), and the remaining eight studies were prospective cohort studies (16, 18, 27–29, 31–33). The publication year ranged between 1998 and 2021. The baseline and clinical characteristics for the included studies are shown in Table 1. Thirteen included studies were performed in the Caucasian population, and two studies were performed in the Asian population.

Four studies reported international disease classification (ICD)-10 criteria, one study used ICD-9, three studies used medical history, and two studies used American academy of pediatrics guidelines as the diagnostic criteria for defining neurodevelopmental disorders. The detailed classes for the antibiotic exposed in all the included studies are represented in Table 1. The classes of antibiotics include Penicillins, sulfonamides, trimethoprim, Pimpicillinam, sulphotimizole macrolides, lincosamides, streptogramins, and other antifungal/antiviral/antibacterial drugs. All included studies had quality levels ranging from moderate [NOS score 4–6] to high [NOS score 7–8] (Table 2). The included studies received quality scores ranging from 6 to 8. In addition, the included studies showed a high risk of comparability bias due to poor confounder adjustment. All included studies are of moderate to high quality, indicating the validity of our findings.

Frontiers in Neurology
FIGURE 1
Flow diagram for the selection of studies and specific reasons for exclusion from the present meta-analysis.
| S. No. | Author, year | Country | Ethnicity | Study design | Study period | Exposure assessment | Diagnosis criteria | Sample size | Age (Years) for assessment of outcome | Antibiotics exposed | Endpoints |
|-------|--------------|---------|-----------|--------------|--------------|---------------------|-------------------|-------------|--------------------------------------|-------------------|-----------|
| 1.    | Lavebratt et al. (27) | Sweden | Caucasian | PCS         | 1996-2012    | Database Records    | ICD-10            | 990,098     | 2 to 18                              | Airway and urinary tract antibiotic | ADHD      |
| 2.    | Hamad et al. (17) | Canada | Caucasian | RCS         | 1998-2017    | Database Records    | AAP               | 187,605     | 4 to 18                              | Penicillin, Other beta lactams, Macrolides and related antibiotics | ADHD      |
| 3.    | Fan et al. (16) | UK      | Caucasian | PCS         | 1990-2016    | Database Records    | NA                | 104,605     | 0 to 14                              | Macrolide, Penicillin | ADHD/ASD/CP/Epilepsy |
| 4.    | Leviton et al. (28) | USA     | Caucasian | PCS         | NA          | Patients Records    | NA                | 583         | 0 to 10                              | antibiotic variable conveys information about bacteremia | ADHD      |
| 5.    | Atladottir et al. (29) | Denmark | Caucasian | PCS         | 1996-2002    | DNBC                | NA                | 976         | 8 to 14                              | Penicillin, sulf drug, other antibiotics or medicine against fungus | ASD       |
| 6.    | Guisso et al. (11) | Lebanon | Asian     | CCS         | NA          | Patients Records    | DSM-IV            | 314         | 2 to 18                              | viral/bacterial infection antibiotics | ASD       |
| 7.    | Isaksson et al. (19) | Sweden | Caucasian | CCS         | NA          | Database Records and Survey | NA                | 415         | 4 to 9                               | viral/bacterial infection antibiotics | ASD       |
| 8.    | Abelson et al. (19) | Israel  | Asian     | NCCS        | 2008-2006    | Database Records    | Medical history    | 451         | NA                                   | Antimicrobial | ASD       |
| 9.    | Hamad et al. (18) | Canada | Caucasian | PCS         | 1998-2016    | Database Records    | AAP               | 2965        | 1 to 18                              | viral/bacterial infection antibiotics | ASD       |
| 10.   | Sasonker-Joseph et al. (30) | Israel | Asian     | RCS         | 1998-2012    | Database Records    | ICD-9             | 23471       | 3 to 18                              | Macrolides and other antibiotics | ASD       |
| 11.   | Miller et al. (31) | Denmark | Caucasian | PCS         | 1996-2004    | Database Records    | ICD-10            | 68820       | 0 to 9.9                             | Pnmecillinam, sulphamethazole | Epilepsy |
| 12.   | Miller et al. (32) | Denmark | Caucasian | PCS         | 1996-2004    | Database Records    | ICD-10            | 172879      | 0 to 5                               | Penicillins, sulfonamides and trimethoprim, macrolides, lincosamides, streptogramins, other antibacterials | Epilepsy |
| 13.   | O’Shea et al. (34) | USA     | Caucasian | CCS         | 1978-1989    | Database Records    | Medical History and Bayley Scale | 240         | 0 to 1                               | Viral/bacterial infection antibiotics | CP        |
| 14.   | Miller et al. (32) | Denmark | Caucasian | PCS         | 1997-2003    | Database Records    | ICD-10            | 131674      | 5 to 6                               | Penicillins,sulfonamides and trimethoprim, macrolides, lincosamides, streptogramins, other antibacterials | CP        |
| 15.   | Meeraus et al. (15) | UK      | Caucasian | RCS         | 1990-2010    | Database Records    | NA                | 64623       | 0 to 3.6                             | Bacterial infection antibiotics | CP/Epilepsy |

PCS, prospective cohort study; RCS, retrospective cohort study; CCS, case-control study; NCCS, nested case-control study; CP, cerebral palsy; NA, not applicable; ADHD, attention-deficit/hyperactivity deficit; ASD, autism spectrum disorder; ICD, international classification of disease; AAP, American academy of pediatrics; DSM-IV, diagnostic and statistical manual of mental disorders.
| S. No. | Author, year | Selection | Comparability | Exposure | Quality score | Quality grade |
|-------|--------------|-----------|---------------|----------|---------------|---------------|
|       |              | Definition of non-exposed group | Representativeness of exposed group | Selection of Non-exposed | Definition of Non-exposed | Outcome of interest was not present at the start of study | Comparability between the groups | Ascertainment of exposure | Same method of ascertainment for exposed and non-exposed group | Adequacy of follow-up |
| 1.    | Lavebratt et al. (27) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 2.    | Hamad et al. (17) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 8 | High |
| 3.    | Fan et al. (16) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 4.    | Leviton et al. (28) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 5.    | Atladottir et al. (29) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 6.    | Guisso et al. (11) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 7.    | Isaksson et al. (19) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 8.    | Abelson et al. (19) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 9.    | Hamad et al. (18) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 10.   | Sassonker-Joseph et al. (30) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 11.   | Miller et al. (31) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 12.   | Miller et al. (32) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 13.   | O’Shea et al. (34) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 6 | Medium |
| 14.   | Miller et al. (32) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 7 | High |
| 15.   | Meeraus et al. (15) | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 6 | Medium |
Association between childhood ASD and prenatal antibiotic exposure

Six studies, including three prospective cohort studies (16, 18, 29), one nested case-control study (20), and two case-control studies (11, 19), explored the link between prenatal maternal antibiotic therapy and the risk of ASD in offspring. Our results showed no overall association between prenatal antibiotic exposure and the risk of ASD [OR = 1.09; 95% CI = 0.88 to 1.31, I² = 78.9%]. Only prospective cohort studies found a significant relationship with the pooled OR of 1.17 (95% CI, 1.03–1.31; Figure 2A), with modest evidence of heterogeneity (P = 0.14; I² = 48.1%) in the subgroup analysis based on the study design.

Association between prenatal antibiotic exposure and childhood ADHD

Pooled analysis of four studies involving three prospective (16, 27, 28) and one retrospective (17) cohort studies showed a strong correlation between prenatal antibiotic exposure and the risk of ADHD [OR = 1.14; 95% CI = 1.13 to 1.15, I² = 0%]. However, subgroup analysis showed a borderline risk of ASD in the prospective cohort [OR = 1.13; 95% CI = 0.97 to 1.29, I² = 24.5%] and a strong association for the risk of ASD in the retrospective cohort [OR = 1.14; 95% CI = 1.11 to 1.17, Figure 2B].

Association between prenatal antibiotic exposure and childhood epilepsy during pregnancy

Four studies (15, 16, 33, 34) looked at the link between prenatal antibiotic therapy and the risk of CP in offspring. There was no significant association between prenatal antibiotic exposure and the risk of CP [OR = 0.99, 95% CI = 0.56 to 1.43, I² = 91%]. Subgroup analysis suggested a significant association between prenatal antibiotic exposure and the risk of CP [OR = 1.18, 95% CI = 1.02 to 1.34, I² = 0%] in all three included prospective cohort studies but not in the retrospective studies [OR = 0.63, 95% CI = 0.54 to 0.73, Figure 2C].

Association between prenatal antibiotic exposure and childhood epilepsy during pregnancy

Five studies including three prospective cohort studies (16, 31, 32) and two retrospective cohort studies (15, 30) looked at the link between antibiotic therapy in pregnant women and the risk of epilepsy in offspring. Overall, prenatal antibiotic exposure was significantly associated with the risk of epilepsy [OR = 1.34, 95% CI = 1.02 to 1.66, I² = 96.8%]. However, these associations were not significant in the subgroup analysis in both prospective [OR = 1.07, 95% CI = 0.95 to 1.19, I² = 71.8%] and retrospective studies [OR = 1.84, 95% CI = 0.70 to 2.97, Figure 2D].

Publication bias

Egger test and Begg’s funnel plot were used to analyzing publication bias for all 15 included studies in our meta-analysis. There was no discernible asymmetry in any included neurodevelopmental disorders based on the visual assessment of the funnel plot (Figures 3A–D). We found no evidence of publication bias in the included studies by Egger’s test.

Sensitivity analyses

Sensitivity analyses were performed to see how each individual study of each neurodevelopmental disorder affected the pooled ORs by omitting individual included studies one at a time. Deleting any individual study did not significantly change the associated pooled ORs (Figures 4A–D), further verifying that the findings of the current meta-analysis are statistically sound and robust.

Discussion

Infections have long been linked to aberrant prenatal brain development, and negative outcomes include cerebral palsy (35), developmental delay (36, 37), epilepsy (38), and schizophrenia (39). However, the reasons behind these associations are still unclear. Several studies suggested that certain maternal infections induce fetal brain impairment (38, 40). Since mothers with these infections are more likely to be treated with antibiotics, maternal infection was considered a confounder in the analyses, and accounting for infections can lead to erroneous results that reflect the infection rather than the therapy. Several meta-analyses have published data on infections that occurred prior to ASD diagnosis (41) and identified a significant positive association of ASD with infections that occurred during pregnancy (42, 43). While one systematic analysis found an elevated risk of ASD after prenatal exposure to various drugs, including antibiotics, the association of the diagnosis with individual drugs was not examined (43). Another meta-analysis revealed no evidence of a link between early postnatal infections and the likelihood of ASD later in life (44). On the other hand, several observational studies have discovered incidences of increased risk of mental illnesses in older children and adults following certain diseases (2, 45). The immune system can be influenced by infections and a dysfunctional gut microbiome. Numerous studies show the role of the immune system, inflammation, and autoimmunity in the etiology of neurodevelopmental and psychiatric disorders in children. Studies showed that the levels of pro-inflammatory cytokines are elevated in children with bipolar and major depressive disorders, posttraumatic stress disorder, obsessive-compulsive disorder, schizophrenia, ADHD, and Tourette’s syndrome (46).
Immune activation has also been linked to the pathogenesis of major depressive disorder (47) and schizophrenia (48) in adults. Recent studies suggest that immunomodulation plays a key role in orchestrating microbiota–gut–brain communication and has the potential to influence neurodevelopment (49–52).

To the best of our knowledge, this is the first systematic review and meta-analysis to examine the link between antibiotic exposure and the risk of neurodevelopmental disorders such as autism, ADHD, CP, and epilepsy. Our findings show a strong connection between prenatal antibiotic exposure and the risk of ADHD and epilepsy. However, we found no significant association between antibiotic exposure during pregnancy and the risk of ASD and CP. While further subgroup analysis based on the type of studies showed a significant correlation between prenatal antibiotic exposure and the risk of ASD and CP in the included prospective cohorts, no such association was found in retrospective studies.

Our findings are consistent with the previously published meta-analysis by Lee et al. (21) for ASD and by Ai et al. (22) for ADHD. There is no meta-analysis available for the possible association between prenatal antibiotic exposure and the risk of CP and epilepsy.

Lee et al. (21) concluded that prenatal antibiotic exposure may increase the risk of ASD in children. This study confirmed that while the use of antibiotics before and after birth raised the risk of ASD, only prenatal antibiotic use was substantially higher in children with ASD compared to children who were not exposed to prenatal treatment. However, the existing studies on the relationship between ASD risk and postnatal antibiotic use do not specifically focus on prenatal antibiotic exposure, making the comparison or evaluation of the risk levels of pre- and post-natal antibiotic use difficult. Another meta-analysis by Ai et al. (22) which included 11 studies suggested the association of prenatal antibiotic treatment with an increased risk of ADHD in children. However, there was a high degree of heterogeneity...
and publication bias in their analysis which may be due to the large disparity in population characteristics, sample size, timing of antibiotic administration, and antibiotic kind. The precision of the reported pooled estimations was also low which limits the applicability of their findings.

In the present meta-analysis, we found a substantial association between prenatal antibiotic exposure and the risk of CP and ASD, as well as an overall association with ADHD and epilepsy. Our results show a strong association between prenatal antibiotic exposure with the increased risk of ADHD and epilepsy development. While our combined results did not indicate that there is a substantial relationship between maternal antibiotic treatment and incidences of ASD and CP in offspring, this association was significant in prospective cohort studies. This could be because neurodevelopmental diseases have multiple causes. For example, non-genetic causes account for 70% of cerebral palsy cases, whereas genetic variables account for 60–70% of epilepsy, ADHD, and ASD cases (53–56).

Our systematic review and meta-analysis have some limitations, and therefore, results must be interpreted with caution. Only a limited number of published studies investigated a high degree of heterogeneity between study outcomes. This may be due to the inclusion of studies with different study designs leading to recall bias for the observed findings. Variability in the available outcomes, such as the type, number, and timing of antibiotic exposures among the included studies, limited our ability to perform further subgroup analyses. Due to the lack of genetic predisposition data, we were not able to correlate our findings with antibiotic exposure.

**Conclusion**

Our data show that prenatal antibiotic exposure during pregnancy is linked to a higher incidence of ADHD and epilepsy in children. Further prospective studies, comparing
FIGURE 4
(A–D) Sensitivity analysis for the association of prenatal exposure to antibiotics and risk of neurodevelopmental disorders in the offspring. (A) Risk of ASD. (B) Risk of ADHD. (C) Risk of CP. (D) Risk of epilepsy.

prenatal antibiotic use with adjustment for various confounders, are needed.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

QT and YS analyzed the data and contributed to the writing of the manuscript. YL, HL, and MY contributed to the data collection and analysis. JG contributed to the substantial review and editing of the manuscript. All authors read and approved the final manuscript.

Funding

This study was funded by a grant from the National Natural Science Foundation of China (No. 82071686), the Science and Technology Bureau of Sichuan province (No. 2021YFS0093), and the Research Fund of West China Second University Hospital (No. KL115, KL072).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Prenatal, perinatal, and neonatal risk factors of autism spectrum disorder.

Neurology (2018) 84:190–8. doi: 10.1038/pr.2018.23

Prog Neuropsychopharmacol Biol Psychiatry. (2018) 48:426–36. doi: 10.1017/S0033291717000745

et al. Prevalence and predictors of antibiotic administration during pregnancy and inflammation, infections, and mental disorders. Psychopathology. (2015) 48:300–1. doi: 10.1002/phar.1649

Associations between maternal infection during pregnancy, childhood infections, and the risk of subsequent psychotic disorder—a Swedish cohort study of nearly 2 million individuals. Schizophr Bull. (2016) 42:125–33. doi: 10.1093/schbul/sbv112

Blomström Å, Karlsson H, Gardner R, Jörgensen L, Magnusson C, Dalman C. Fever and infections during pregnancy and cerebral palsy in very low birth weight infants. Paediatr Perinat Epidemiol. (2018) 32:317–24. doi: 10.1111/ppe.12082

Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of very low birth weight. JAMA Neurol. (2020) 77:909–14. doi: 10.1001/jamaneurol.2020.1789

J Clin Psychiatry. (2021) 82:28–34. doi: 10.1097/JCP.0000000000000908

J Autism Dev Disord. (2018) 49:317–26. doi: 10.1002/ajd.25515

Mol Psychiatry. (2021) 26:555–67. doi: 10.1038/s41398-020-00877-x

Mol Psychiatry. (2021) 26:1451–63. doi: 10.1038/s41398-020-01043-4

Anticentors of screening positive for attention deficit hyperactivity disorder in ten-year-old children born extremely preterm. Pediatr Neurosurg. (2018) 54:398–409. doi: 10.1159/000487880

Transl Psychiatry. (2019) 9:317. doi: 10.1038/s41398-019-0653-9

Front Neurol. (2020) 11:594. doi: 10.3389/fneur.2020.00594

Frontiers in Neurology 11

References

1. Estes ML, McAllister AK. Maternal immune activation: implications for neuropsychiatric disorders. Science. (2016) 353:772–7. doi: 10.1126/science.aag3194

2. Benros ME, Wahllof BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry. (2013) 70:812–20. doi: 10.1001/jamapsychiatry.2013.1111

3. Khandaker GM, Dantzer R, Jones PB. Immunopsychiatry: important facts. Psychol Med. (2017) 47:2229–37. doi: 10.1017/S0033291717000745

4. Rice D, Barone S. Critical periods of vulnerability for the developing nervous system: prenatal, perinatal, and neonatal. Environ Health Perpect. (2000) 108 Suppl 3:511–33. doi: 10.1289/ehp.000815111

5. Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLachlin M, et al. Review of antibiotic use in pregnancy. Pharmacotherapy. (2015) 35:1052–62. doi: 10.1002/phar.1649

6. Kuperman AA, Koren O. Antibiotic use during pregnancy: how bad is it? BMC Med. (2016) 14:91. doi: 10.1186/s12916-016-0366-0

7. Broe A, Pottegård A, Lamont RF, Jørgensen JS, Damkier P. Increasing use of antibiotics in pregnancy during the period 2000–2010: prevalence, timing, category, and demographics. BJOG Int J Obstet Gynaecol. (2012) 119:988–96. doi: 10.1111/j.1471-0528.2012.03306.x

8. Støkeloh M, Schjørring S, Pedersen L, Bischoff AL, Feijsgaard N, Carson CG, et al. Prevalence and predictors of antibiotic administration during pregnancy and birth. PLoS ONE. (2013) 8:e92932. doi: 10.1371/journal.pone.0092932

9. Degroote S, Hunting DJ, Baccarelli AA, Takser L. Fever and infections during pregnancy and attention-deficit/hyperactivity disorder: a population-based study within the Danish national birth cohort study. PLoS ONE. (2013) 8:e82932. doi: 10.1371/journal.pone.0082932

10. Hisle-Gorman E, Susi A, Stokes T, Gorman G, Erdie-Lalena C, Nylund CM. Antibiotic exposure and risk of attention-deficit/hyperactivity disorder-A nested case-control study. Front Psychiatry. (2021) 12:771232. doi: 10.3389/fpsyt.2021.771232

11. Lee E, Cho J, Kim KY. The association between autism spectrum disorder and pre- and postnatal antibiotic exposure in childhood-a meta-review with meta-analysis. Int J Environ Res Public Health. (2019) 16:54022. doi: 10.3390/ijerph16040424

12. Ai Y, Zhao J, Shi J, Zhu TT. Antibiotic exposure and childhood attention-deficit/hyperactivity disorder: systematic review and meta-analysis. Psychopharmacology. (2021) 238:3055–62. doi: 10.1007/s00213-021-05989-3

13. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. (2015) 4:1. doi: 10.1186/2045-403X-4-1

14. Flinkkilä E, Keski-Rahkonen A, Marttunen M, Raevuori A. Prenatal infection, febrile episodes, and antibiotic use during pregnancy: an exploratory study. Pediatr (2012) 130:e1447–1454. doi: 10.1542/peds.2012-1107

15. Leviton A, Hooper SR, Hunter SJ, Scott MN, Alfred EN, Joseph RM, et al. ELGAN study investigators. Antecedents of screening positive for attention deficit hyperactivity disorder in ten-year-old children born extremely preterm. Pediatr Neurol. (2018) 81:25–30. doi: 10.1016/j.pediatrneur.2017.12.010

16. Atladottir HO, Henriksen TB, Schendel DE, Parner ET. Autism after infection, febrile episodes, and antibiotic use during pregnancy: a nationwide study. Transl Psychiatry. (2019) 9:317. doi: 10.1038/s41398-019-0653-9

17. Hamad AF, Alessi-Severini S, Mahmud SM, Brownell M, Kuo IF. Prenatal antibiotic exposure and the risk of childhood febrile seizures: a Danish population-based cohort. PLoS One. (2013) 8:e61148. doi: 10.1371/journal.pone.0061148

18. Wu YW, Colford JM. Chorioamnionitis as a risk factor for cerebral palsy: a nested case-control study. Paediatr Perinat Epidemiol. (2019) 33:274–52. doi: 10.1111/ppe.12802

19. O’Shea TM, Klinepeter KL, Dillard RG. Prenatal events and the risk of cerebral palsy in very low birth weight infants. Am J Epidemiol. (1998) 147:362–9. doi: 10.1093/oxfordjournals.aje.a019054

20. Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth weight. JAMA. (1997) 278:207–11.

21. Miller JE, Pedersen LH, Sun Y, Olsen J. Maternal use of cistis medication and childhood epilepsy in a Danish population-based cohort. Paediatr Perinat Epidemiol. (2012) 26:589–95. doi: 10.1111/j.1600-0425.2012.01317.x

22. Miller JE, Pedersen LH, Vestergaard M, Olsen J. Maternal use of antibiotics and the risk of childhood febrile seizures: a Danish population-based cohort. PLoS One. (2013) 8:e61148. doi: 10.1371/journal.pone.0061148

23. Miller JE, Pedersen LH, Streja E, Bech BH, Yeungin-Allopp M, Van Naarden Braun K, et al. Maternal infections during pregnancy and cerebral palsy: a population-based cohort study. Paediatr Perinat Epidemiol. (2013) 27:542–52. doi: 10.1111/ppe.12082

24. Wu YW, Colford JM. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. JAMA. (2000) 284:1417–24. doi: 10.1001/jama.284.11.1417

25. Modabbernia A, Velthorst E, Reichenberg A. Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses. Mol Autism. (2017) 8:13. doi: 10.1186/s13229-017-0121-4
42. Jiang HY, Xu LL, Shao L, Xia RM, Yu ZH, Ling ZX, et al. Maternal infection during pregnancy and risk of autism spectrum disorders: a systematic review and meta-analysis. Brain Behav Immun. (2016) 58:165–72. doi: 10.1016/j.bbi.2016.06.005

43. Gardener H, Spiegelman D, Buka SL. Prenatal risk factors for autism: comprehensive meta-analysis. Br J Psychiatry J Ment Sci. (2009) 195:7–14. doi: 10.1192/bjp.bp.108.051672

44. Gardener H, Spiegelman D, Buka SL. Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis. Pediatrics. (2011) 128:544–55. doi: 10.1542/peds.2010-1036

45. Köhler O, Petersen L, Mors O, Mortensen PB, Yolken RH, Gasse C, et al. Infections and exposure to anti-infective agents and the risk of severe mental disorders: a nationwide study. Acta Psychiatr Scand. (2017) 135:97–105. doi: 10.1111/acps.12671

46. Mitchell RHB, Goldstein BI. Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review. J Am Acad Child Adolesc Psychiatry. (2014) 53:274–96. doi: 10.1016/j.jaac.2013.11.013

47. Dantzer R, O Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. (2008) 9:46–56. doi: 10.1038/nrn2397

48. Schwarz R, Bruno JP, Muchowski PJ, Wu H-Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. (2012) 13:465–77. doi: 10.1038/nrr3257

49. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci. (2017) 20:145–55. doi: 10.1038/nrn4476

50. Rothhammer V, Mascalfroni ID, Bunse L, Takanaka MC, Kenison JE, Mayo L, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med. (2016) 22:586–97. doi: 10.1038/nm.4106

51. Braniste V, Al Asma M, Kowal C, Anuar F, Abbaspour A, Töth M, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. (2014) 6:263ra158. doi: 10.1126/scitranslmed.3009759

52. Erny D, Hrabè de Angelis AL, Jaitin D, Wiegäßer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. (2015) 18:965–77. doi: 10.1038/nn.4030

53. Hildebrand MS, Dahl H-HM, Damiano JA, Smith RJH, Scheffer IE, Berkovic SF. Recent advances in the molecular genetics of epilepsy. J Med Genet. (2013) 50:271–9. doi: 10.1136/jmedgenet-2012-101448

54. MacLennan AH, Thompson SC, Gecz J. Cerebral palsy: causes, pathways, and the role of genetic variants. Am J Obstet Gynecol. (2015) 213:779–88. doi: 10.1016/j.ajog.2015.05.034

55. Faraone SV, Asherson P, Banaschewski T, Biederman J, Brambilla P, Carter JC, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. (2015) 1:15020. doi: 10.1038/nrdp.2015.20

56. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. (2004) 113:e472–486. doi: 10.1542/peds.113.5.e472